Novo Nordisk Pulls Unlucky NovoSeven Application In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.